Jefferies Maintains a Buy Rating on Ardelyx (ARDX) With an $8 Price Target
Ardelyx Inc. (NASDAQ:ARDX) is one of the 13 Stocks Under $5 With High Upside Potential. On July 2, Jefferies analyst Dennis Ding maintained a Buy rating on Ardelyx Inc.
Ardelyx Inc. (ARDX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Marshall Wace LLP Paul Marshall And Ian Wace | 8,383,809 | $41,164,504 | +7202% | 0.05% |
| 2. | Millennium Management Israel Englander | 6,465,262 | $31,744,436 | +119% | 0.02% |
| 3. | Citadel Investment Group Ken Griffin | 3,190,355 | $15,664,643 | +29% | 0% |
| 4. | Two Seas Capital Sina Toussi | 2,120,337 | $10,410,855 | +15% | 0.33% |
| 5. | D E Shaw D. E. Shaw | 1,916,525 | $9,410,138 | +31% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.63 | 200,000 | $725,880.00 | 2,896,871 | 2025-06-16 | Filing | |
| $3.69 | 200,000 | $737,260.00 | 2,696,871 | 2025-06-09 | Filing | |
| $3.29 | 100,000 | $329,120.00 | 2,496,871 | 2025-05-15 | Filing | |
| $4.22 | 381,377 | $1,610,936.45 | 2,396,871 | 2025-05-02 | Filing | |
| $5.00 | 77,729 | $388,738.27 | 2,015,494 | 2025-02-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.08 | 6,421 | $26,206.67 | 402,583 | 2025-05-20 | Filing | |
| $4.08 | 7,218 | $29,459.55 | 416,089 | 2025-05-20 | Filing | |
| $4.08 | 46,817 | $191,078.90 | 1,547,937 | 2025-05-20 | Filing | |
| $4.08 | 14,522 | $59,270.09 | 282,158 | 2025-05-20 | Filing | |
| $4.08 | 5,992 | $24,455.75 | 311,731 | 2025-05-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,000 | $7,840 | 0% | |
| 2. | 835 | $3,273 | 0% |
News See All
13 Stocks Under $5 With High Upside Potential
On July 1, Ralph Schlosstein, Evercore chairman emeritus and BlackRock co-founder, appeared on CNBC's 'Closing Bell Overtime' to discuss his outlook for markets heading into the second half of 2025.
Ardelyx (ARDX) Appoints New Chief Business and HR Officers
Ardelyx, Inc. (NASDAQ:ARDX) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company announced two key appointments to its leadership team.
10 Best Healthcare Penny Stocks to Buy According to Analysts
According to the Centers for Medicare & Medicaid Services (CMS), the US healthcare sector accounted for approximately 17.6% of GDP in 2023.
H.C. Wainwright Initiates Coverage of Ardelyx (ARDX) Stock, Gives Buy
Ardelyx, Inc. (NASDAQ:ARDX) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, H.C.
Leerink Partners Maintains a Buy Rating on Ardelyx (ARDX) With a $10 PT
Ardelyx Inc. (NASDAQ:ARDX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On May 2, Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Ardelyx Inc.
13 Best Long-Term Penny Stocks to Buy According to Analysts
On June 18, Société Générale's Subadra Rajappa appeared on CNBC to talk about her expectations from the Fed.
10 Worst Aggressive Growth Stocks to Buy According to Short Sellers
According to Morningstar, stocks have experienced a healthy recovery over the past few months. However, the momentum was insufficient to propel the market to a new high for the year.
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2025 Earnings Call Transcript
Operator: Good day everyone and welcome to the Ardelyx’s First Quarter 2025 Earnings. All participants will be in a listen-only mode.
13 Best Biotech Penny Stocks to Buy According to Hedge Funds
Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas.
Billionaire Hedge Funds
